NSN 6505-01-725-2767 · NIIN 017252767 · FSC 6505
NO DASHES 6505017252767
In Stock
PYRIDOSTIGMINE BROMIDE TABLETS
Drugs and Biologicals
Technical characteristics
6 rows
Straight from the federal item record. Entries the record leaves empty are shown empty — nothing is filled in on its behalf.
| MRC | Requirement | Value |
|---|---|---|
| AKJA | ACTIVE MEDICAMENT MEDICINAL STRENGTH | MILLIGRAMS PYRIDOSTIGMINE BROMIDE ACTIVE INGREDIENT 105.0 |
| FEAT | SPECIAL FEATURES | FOR MILITARY MEDICAL USE ONLY; INDICATED FOR PRE-TREATMENT AGAINST THE LETHAL EFFECTS OF SOMAN NERVE AGENT POISONING IN ADULTS; USE IN CONJUNCTION WITH PROTECTIVE GARMENTS, INCLUDING A MASK; STORE AT 20 C TO 25 C (68 F TO 77 F); EXCURSIONS PERMITTED BETWEEN 15 C TO 30 C (59 F TO 86 F) (SEE USP CONTROLLED ROOM TEMPERATURE), OR STORE REFRIGERATED BETWEEN 2 C AND 8 C (36 F TO 46 F). PROTECT FROM HEAT AND MOISTURE. DISCARD CONTENTS OF BLISTER PACK 3 MONTHS AFTER THE MYLAR BAG IS OPENED; EACH EXTENDED-RELEASE TABLETS CONTAIN 105 MG OF PYRIDOSTIGMINE BROMIDE (EQUIVALENT TO 72.87 MG OF PYRIDOSTIGMINE BASE) FOR ORAL ADMINISTRATION; BAG OF 10 BLISTER PACK, EACH BLISTER PACK CONTAINS 7 TABLETS. |
| AKJF | LONG ACTION METHOD | EXTENDED RELEASE |
| CSGS | ADMINISTRATION | ORAL |
| CXCY | PART NAME ASSIGNED BY CONTROLLING AGENCY | PYRIDOSTIGMINE BROMIDE EXTENDED-RELEASE TABLETS, 105MG, 70S |
| CSCW | TOTAL PRIMARY CONTAINER QUANTITY | 70 |
Cross-references
3 manufacturer part numbers on file for this NSN — each shown against the CAGE code it belongs to.
| Manufacturer part number | CAGE |
|---|---|
| NDC60846-0559-10 | 557X3 |
| 6505NCM241134 | 64616 |
| 1678145 | 89875 |